Trinity Biotech plc (NASDAQ:TRIB) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Thursday.

According to Zacks, “Trinity Biotech plc, headquartered in Bray, the Republic of Ireland, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market worldwide. The company provides two haemostasis product lines, Biopool and Amax, comprising test kits and instrumentation used for the detection of blood disorders. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the blood, liver and intestine. The Company is also a provider of raw materials to the life sciences industry. It also engages in the provision of engineering, financial, and management services, as well as in trading business. Trinity Biotech sells its products through its sales force, as well as through a network of distributors and strategic partners. “

Shares of Trinity Biotech plc (NASDAQ:TRIB) opened at 12.75 on Thursday. The company has a market capitalization of $293.45 million, a PE ratio of 54.26 and a beta of 0.92. The stock has a 50 day moving average of $12.83 and a 200-day moving average of $11.74. Trinity Biotech plc has a 12-month low of $9.20 and a 12-month high of $13.68.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/trinity-biotech-plc-trib-upgraded-by-zacks-investment-research-to-hold-2.html

Trinity Biotech plc (NASDAQ:TRIB) last announced its quarterly earnings results on Thursday, July 21st. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.03. The firm had revenue of $26.30 million for the quarter, compared to analyst estimates of $24.30 million. Analysts predict that Trinity Biotech plc will post $0.14 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Raymond James & Associates boosted its position in Trinity Biotech plc by 5.3% in the second quarter. Raymond James & Associates now owns 29,823 shares of the company’s stock worth $338,000 after buying an additional 1,489 shares during the last quarter. State Street Corp boosted its position in Trinity Biotech plc by 100.7% in the second quarter. State Street Corp now owns 34,953 shares of the company’s stock worth $396,000 after buying an additional 17,539 shares during the last quarter. DIAM Co. Ltd. boosted its position in Trinity Biotech plc by 0.6% in the second quarter. DIAM Co. Ltd. now owns 81,300 shares of the company’s stock worth $922,000 after buying an additional 500 shares during the last quarter. Benchmark Capital Advisors boosted its position in Trinity Biotech plc by 9.0% in the second quarter. Benchmark Capital Advisors now owns 91,041 shares of the company’s stock worth $1,032,000 after buying an additional 7,500 shares during the last quarter. Finally, Kimelman & Baird LLC boosted its position in Trinity Biotech plc by 0.6% in the first quarter. Kimelman & Baird LLC now owns 109,367 shares of the company’s stock worth $1,275,000 after buying an additional 675 shares during the last quarter.

About Trinity Biotech plc

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.

5 Day Chart for NASDAQ:TRIB

Receive News & Ratings for Trinity Biotech plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech plc and related companies with MarketBeat.com's FREE daily email newsletter.